Search the Newsreel

Abbott Reports Second-Quarter 2026 Results and Raises Full-Year EPS Guidance

Abbott (NYSE: ABT) announced its second-quarter 2026 financial results, reporting substantial growth and raising its full-year EPS guidance. The company achieved 13.0 percent reported sales growth and 4.8 percent comparable sales growth, with GAAP diluted EPS of $0.53 and adjusted diluted EPS of $1.31. …

Why Abbott Laboratories Stock Is Suddenly Winning Back Wall Street

Abbott Laboratories' Q2 earnings report has reassured Wall Street, demonstrating that its integration of Exact Sciences is progressing better than anticipated, leading to solid growth and improved profitability metrics. The company reported 13% growth and 4.8% organic growth, exceeding adjusted EPS forecasts and prompting …

Abbott Laboratories, AtaiBeckley, ManpowerGroup And Other Big Stocks Moving Higher On Thursday

Several major stocks, including Abbott Laboratories, AtaiBeckley, and ManpowerGroup, saw significant gains on Thursday. Abbott Laboratories shares jumped after reporting better-than-expected quarterly results and raising its FY26 EPS guidance. AtaiBeckley surged following an acquisition announcement by Lilly, while ManpowerGroup also rose due to strong …

Abbott Is On Deck to Launch Several New Devices

Abbott is expected to launch several new medical devices, signaling the company's return to relying on innovative products across its divisions as market conditions normalize post-pandemic. The article, authored by Debbie S. Wang, also referenced strong second-quarter earnings that eased jitters from a softer …

Abbott Stock Is Leading the S&P 500 After Earnings for Its Best Day in 24 Years

Abbott Laboratories' stock saw its best day in 24 years, leading the S&P 500 after reporting better-than-expected earnings for its second quarter. The company also raised its full-year profit outlook, driven by improved sales in its nutrition segment.

Abbott Laboratories shares jump as earnings beat estimates and company raises 2026 outlook

Abbott Laboratories (NYSE:ABT) saw its shares rise by nearly 11% after reporting strong second-quarter 2026 results that surpassed Wall Street expectations, with adjusted diluted EPS of $1.31 and revenue of $12.59 billion. The company raised its full-year adjusted diluted EPS guidance to $5.45 to …

Abbott, Up 14%, Strikes Three-Month High After Boosting 2026 Profit Outlook

Abbott stock surged to a three-month high after the company raised its full-year earnings outlook for 2026. This positive revision follows a strong second-quarter report. The new guidance indicates an adjusted earnings per share of $5.45 to $5.60, an increase of about 4 cents …

Why Abbott Stock Is Reimagining Its Future

Abbott (ABT) is undergoing a significant strategic shift, moving its focus and capital allocation away from its volatile Nutrition segment towards high-margin, innovation-led MedTech and specialized diagnostics. This pivot involves stabilizing the Nutrition segment's margins through strategic pricing despite declining sales, while aggressively expanding …

Is Abbott Laboratories (ABT) Below Fair Value After Its 31% Fall?

Abbott Laboratories (ABT) has experienced a 31% stock price fall over the past year, leading to investor sentiment turning negative. However, both discounted cash flow (DCF) analysis and traditional market multiples suggest the shares are currently trading at a discount. Despite potential risks like …

Abbott Laboratories Sales Rise on Diagnostics Growth

Abbott Laboratories reported higher revenue in the second quarter, primarily driven by increased sales in its diagnostics business. Despite the revenue boost, the company's profit for the quarter fell to $928 million from $1.78 billion in the prior year. Abbott also raised its full-year …

What Investors Don’t Understand About Abbott Laboratories

Abbott Laboratories (ABT) is undervalued by investors who still perceive it as a slow-growth bond proxy, despite significant transformations. The company's medical devices segment, particularly the FreeStyle Libre, is driving strong growth, and a recent $21 billion acquisition of Exact Sciences is set to …

Abbott eleva su previsión de beneficio por acción para 2026

Abbott Boosts 2026 Profit Guidance as Sales Across Business Rise

Abbott Laboratories has increased its 2026 profit guidance following a better-than-expected second quarter. The company now anticipates adjusted earnings per share to be between $5.45 and $5.60, representing a 5-cent improvement at the midpoint. This positive outlook is attributed to strong performance across most …

Abbott-Aktie schießt nach Q2-Zahlen hoch: Gewinn bricht ein, FY26-EPS-Prognose steigt

Reasons to Retain Abbott Stock in Your Portfolio for Now

Abbott Laboratories (ABT) is recommended as a stock to retain due to strong performance in its Nutrition business and growth in emerging markets within its Established Pharmaceuticals Division (EPD). However, potential headwinds include currency fluctuations, a dull macroeconomic environment, and increased operating costs. The …

Can Abbott (ABT) Turn Freenome Progress Into a Durable Diagnostics-Led Growth Story?

Abbott Laboratories is set to release its Q2 2026 results, with recent progress in diagnostics, particularly its collaboration with Freenome for blood-based colorectal cancer screening, as a key focus. This development could reshape Abbott's investment narrative towards diagnostics-led growth, helping to offset challenges in …

Abbott Laboratories (ABT) Stock Analysis: Potential 23.82% Upside Amid Strong Buy Ratings

Abbott Laboratories stock gains as Norges Bank acquires new institutional position

Abbott Laboratories (ABT) Stock Analysis: Tapping Into A 35.73% Potential Upside

Abbott Laboratories, Coca-Cola, and Walmart: Top Recession-Proof Stocks for 2026 - News and Statistics

Why is Abbott Laboratories stock down today?

Abbott stock tumbles below key moving averages as sellers dominate momentum: weekly outlook

-3.05% for Abbott Laboratories stock as persistent selling outweighs support

Abbott Labs Q4 2025: Revenue Miss, Device Growth & Exact Sciences Acquisition - News and Statistics

Abbott Laboratories stock consolidates as bearish momentum continues after weak technical signals

Abbott Laboratories (ABT) Stock: CEO Snaps Up $2M in Shares Despite Rough Quarter

ABBOTT LABORATORIES PE Ratio (TTM): 35.56 — Near Median